- Home
- BGMS vs DCOY Comparison
BGMS vs DCOY Comparison
Compare BGMS & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGMS | DCOY |
|---|---|---|
| Founded | 1996 | N/A |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 4.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BGMS | DCOY |
|---|---|---|
| Price | $1.04 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 146.0K | ★ 228.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $137.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $0.62 |
| 52 Week High | $6.70 | $1.41 |
Technical Indicators
Market Signals| Indicator | BGMS | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 52.22 |
| Support Level | $0.98 | $0.67 |
| Resistance Level | $1.06 | $0.82 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 58.21 | 82.18 |
Price Performance
Historical ComparisonAbout BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
About DCOY Decoy Therapeutics Inc. Common Stock
Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.